Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report

Immunoglobulin light chain amyloidosis (AL amyloidosis) is characterized by the deposition of abnormal amyloid protein produced by a pathological plasma cell clone in various organs and soft tissues. Hematopoietic stem cell transplantation (HSCT) is an effective way to treat AL amyloidosis. Psoriasi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicine (Baltimore) 2018-12, Vol.97 (50), p.e13589-e13589
Hauptverfasser: Chen, Wencui, Ren, Guisheng, Zuo, Ke, Huang, Xianghua
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e13589
container_issue 50
container_start_page e13589
container_title Medicine (Baltimore)
container_volume 97
creator Chen, Wencui
Ren, Guisheng
Zuo, Ke
Huang, Xianghua
description Immunoglobulin light chain amyloidosis (AL amyloidosis) is characterized by the deposition of abnormal amyloid protein produced by a pathological plasma cell clone in various organs and soft tissues. Hematopoietic stem cell transplantation (HSCT) is an effective way to treat AL amyloidosis. Psoriasis is a common autoimmune disease (AID) and HSCT is a potential treatment for severe AIDs. We report a rare case of AL amyloidosis coincidence with psoriasis obtained continuous complete remission of the 2 diseases by autologous hematopoietic stem cell transplantation (ASCT). A 58-year-old man with a 30-year history of psoriasis complaining of edema and hypotension for 2 weeks was referred to our institution. His urine protein was quantified 2.83 g/day, without hematuria and decrease of glomerular filtration rate. Renal biopsy confirmed AL amyloidosis and multiple myeloma was excluded by bone marrow cytomorphologic examination. Chemotherapy regimen based on bortezomib and thalidomide had achieved hematologic partial remission, but the kidney had no response and psoriasis was still active. Furthermore, he received a standard myeloablative conditioning with high dose melphalan followed by ASCT. The erythema with slivery scales of psoriasis vulgaris gradually improved and almost disappeared after granulocyte implantation. He obtained persistent hematological complete remission, organ response and recovery of psoriasis. We report a rare case of AL amyloidosis coincidence with psoriasis treated by ASCT. The outcome of this patient indicated that ASCT has therapeutic values both in AL amyloidosis and AIDs.
doi_str_mv 10.1097/MD.0000000000013589
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6320088</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>30558027</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3816-b0dd07d2e2098cc9c8e6d783b3f381710da122af290c59b1a9f0acd60408de0a3</originalsourceid><addsrcrecordid>eNpdUdtu1DAQtRAVXQpfgIT8A2nHdi42D0jVlhakVrzAczSxnY3BiSPbadUv4Xeb7UKB-sWemXMZ-RDyjsEpA9Wc3Vycwt_DRCXVC7JhlaiLStXlS7IB4FXRqKY8Jq9T-rEHNbx8RY4FVJUE3mzIr20YZ2-zpdGOLiUXJhp62oU8UDeOyxR2PnSLdxP1bjdkqgdc3zje--BMSC5RnAydU4gOH6s-20hxycGHXVgSHeyIOczB2ew0TdmOVFvvaY44pdnjlDGvrh_oOdWY9nvMIeY35KhHn-zb3_cJ-X756dv2c3H99erL9vy60EKyuujAGGgMtxyU1FppaWvTSNGJfp03DAwyzrHnCnSlOoaqB9SmhhKksYDihHw86M5LN1qj7bTu5ds5uhHjfRvQtf9PJje0u3Db1oIDSLkKiIOAjiGlaPsnLoN2n1N7c9E-z2llvf_X9onzJ5gVUB4Ad8GvH5p--uXOxnaw6PPwqFc1ihccmGSclVCsnboWDxR1o8E</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report</title><source>Wolters Kluwer Open Health</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>IngentaConnect Free/Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Chen, Wencui ; Ren, Guisheng ; Zuo, Ke ; Huang, Xianghua</creator><creatorcontrib>Chen, Wencui ; Ren, Guisheng ; Zuo, Ke ; Huang, Xianghua</creatorcontrib><description>Immunoglobulin light chain amyloidosis (AL amyloidosis) is characterized by the deposition of abnormal amyloid protein produced by a pathological plasma cell clone in various organs and soft tissues. Hematopoietic stem cell transplantation (HSCT) is an effective way to treat AL amyloidosis. Psoriasis is a common autoimmune disease (AID) and HSCT is a potential treatment for severe AIDs. We report a rare case of AL amyloidosis coincidence with psoriasis obtained continuous complete remission of the 2 diseases by autologous hematopoietic stem cell transplantation (ASCT). A 58-year-old man with a 30-year history of psoriasis complaining of edema and hypotension for 2 weeks was referred to our institution. His urine protein was quantified 2.83 g/day, without hematuria and decrease of glomerular filtration rate. Renal biopsy confirmed AL amyloidosis and multiple myeloma was excluded by bone marrow cytomorphologic examination. Chemotherapy regimen based on bortezomib and thalidomide had achieved hematologic partial remission, but the kidney had no response and psoriasis was still active. Furthermore, he received a standard myeloablative conditioning with high dose melphalan followed by ASCT. The erythema with slivery scales of psoriasis vulgaris gradually improved and almost disappeared after granulocyte implantation. He obtained persistent hematological complete remission, organ response and recovery of psoriasis. We report a rare case of AL amyloidosis coincidence with psoriasis treated by ASCT. The outcome of this patient indicated that ASCT has therapeutic values both in AL amyloidosis and AIDs.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000013589</identifier><identifier>PMID: 30558027</identifier><language>eng</language><publisher>United States: the Author(s). Published by Wolters Kluwer Health, Inc</publisher><subject>Antineoplastic Agents - therapeutic use ; Bortezomib - therapeutic use ; Clinical Case Report ; Hematopoietic Stem Cell Transplantation - methods ; Hematopoietic Stem Cell Transplantation - standards ; Humans ; Immunoglobulin Light-chain Amyloidosis - complications ; Immunoglobulin Light-chain Amyloidosis - drug therapy ; Immunosuppressive Agents - therapeutic use ; Male ; Melphalan - therapeutic use ; Middle Aged ; Psoriasis - complications ; Psoriasis - drug therapy ; Thalidomide - therapeutic use ; Transplantation, Autologous - methods</subject><ispartof>Medicine (Baltimore), 2018-12, Vol.97 (50), p.e13589-e13589</ispartof><rights>the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3816-b0dd07d2e2098cc9c8e6d783b3f381710da122af290c59b1a9f0acd60408de0a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320088/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320088/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30558027$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Wencui</creatorcontrib><creatorcontrib>Ren, Guisheng</creatorcontrib><creatorcontrib>Zuo, Ke</creatorcontrib><creatorcontrib>Huang, Xianghua</creatorcontrib><title>Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Immunoglobulin light chain amyloidosis (AL amyloidosis) is characterized by the deposition of abnormal amyloid protein produced by a pathological plasma cell clone in various organs and soft tissues. Hematopoietic stem cell transplantation (HSCT) is an effective way to treat AL amyloidosis. Psoriasis is a common autoimmune disease (AID) and HSCT is a potential treatment for severe AIDs. We report a rare case of AL amyloidosis coincidence with psoriasis obtained continuous complete remission of the 2 diseases by autologous hematopoietic stem cell transplantation (ASCT). A 58-year-old man with a 30-year history of psoriasis complaining of edema and hypotension for 2 weeks was referred to our institution. His urine protein was quantified 2.83 g/day, without hematuria and decrease of glomerular filtration rate. Renal biopsy confirmed AL amyloidosis and multiple myeloma was excluded by bone marrow cytomorphologic examination. Chemotherapy regimen based on bortezomib and thalidomide had achieved hematologic partial remission, but the kidney had no response and psoriasis was still active. Furthermore, he received a standard myeloablative conditioning with high dose melphalan followed by ASCT. The erythema with slivery scales of psoriasis vulgaris gradually improved and almost disappeared after granulocyte implantation. He obtained persistent hematological complete remission, organ response and recovery of psoriasis. We report a rare case of AL amyloidosis coincidence with psoriasis treated by ASCT. The outcome of this patient indicated that ASCT has therapeutic values both in AL amyloidosis and AIDs.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Bortezomib - therapeutic use</subject><subject>Clinical Case Report</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Hematopoietic Stem Cell Transplantation - standards</subject><subject>Humans</subject><subject>Immunoglobulin Light-chain Amyloidosis - complications</subject><subject>Immunoglobulin Light-chain Amyloidosis - drug therapy</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Male</subject><subject>Melphalan - therapeutic use</subject><subject>Middle Aged</subject><subject>Psoriasis - complications</subject><subject>Psoriasis - drug therapy</subject><subject>Thalidomide - therapeutic use</subject><subject>Transplantation, Autologous - methods</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUdtu1DAQtRAVXQpfgIT8A2nHdi42D0jVlhakVrzAczSxnY3BiSPbadUv4Xeb7UKB-sWemXMZ-RDyjsEpA9Wc3Vycwt_DRCXVC7JhlaiLStXlS7IB4FXRqKY8Jq9T-rEHNbx8RY4FVJUE3mzIr20YZ2-zpdGOLiUXJhp62oU8UDeOyxR2PnSLdxP1bjdkqgdc3zje--BMSC5RnAydU4gOH6s-20hxycGHXVgSHeyIOczB2ew0TdmOVFvvaY44pdnjlDGvrh_oOdWY9nvMIeY35KhHn-zb3_cJ-X756dv2c3H99erL9vy60EKyuujAGGgMtxyU1FppaWvTSNGJfp03DAwyzrHnCnSlOoaqB9SmhhKksYDihHw86M5LN1qj7bTu5ds5uhHjfRvQtf9PJje0u3Db1oIDSLkKiIOAjiGlaPsnLoN2n1N7c9E-z2llvf_X9onzJ5gVUB4Ad8GvH5p--uXOxnaw6PPwqFc1ihccmGSclVCsnboWDxR1o8E</recordid><startdate>20181201</startdate><enddate>20181201</enddate><creator>Chen, Wencui</creator><creator>Ren, Guisheng</creator><creator>Zuo, Ke</creator><creator>Huang, Xianghua</creator><general>the Author(s). Published by Wolters Kluwer Health, Inc</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20181201</creationdate><title>Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report</title><author>Chen, Wencui ; Ren, Guisheng ; Zuo, Ke ; Huang, Xianghua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3816-b0dd07d2e2098cc9c8e6d783b3f381710da122af290c59b1a9f0acd60408de0a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Bortezomib - therapeutic use</topic><topic>Clinical Case Report</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Hematopoietic Stem Cell Transplantation - standards</topic><topic>Humans</topic><topic>Immunoglobulin Light-chain Amyloidosis - complications</topic><topic>Immunoglobulin Light-chain Amyloidosis - drug therapy</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Male</topic><topic>Melphalan - therapeutic use</topic><topic>Middle Aged</topic><topic>Psoriasis - complications</topic><topic>Psoriasis - drug therapy</topic><topic>Thalidomide - therapeutic use</topic><topic>Transplantation, Autologous - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Wencui</creatorcontrib><creatorcontrib>Ren, Guisheng</creatorcontrib><creatorcontrib>Zuo, Ke</creatorcontrib><creatorcontrib>Huang, Xianghua</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Wencui</au><au>Ren, Guisheng</au><au>Zuo, Ke</au><au>Huang, Xianghua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2018-12-01</date><risdate>2018</risdate><volume>97</volume><issue>50</issue><spage>e13589</spage><epage>e13589</epage><pages>e13589-e13589</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Immunoglobulin light chain amyloidosis (AL amyloidosis) is characterized by the deposition of abnormal amyloid protein produced by a pathological plasma cell clone in various organs and soft tissues. Hematopoietic stem cell transplantation (HSCT) is an effective way to treat AL amyloidosis. Psoriasis is a common autoimmune disease (AID) and HSCT is a potential treatment for severe AIDs. We report a rare case of AL amyloidosis coincidence with psoriasis obtained continuous complete remission of the 2 diseases by autologous hematopoietic stem cell transplantation (ASCT). A 58-year-old man with a 30-year history of psoriasis complaining of edema and hypotension for 2 weeks was referred to our institution. His urine protein was quantified 2.83 g/day, without hematuria and decrease of glomerular filtration rate. Renal biopsy confirmed AL amyloidosis and multiple myeloma was excluded by bone marrow cytomorphologic examination. Chemotherapy regimen based on bortezomib and thalidomide had achieved hematologic partial remission, but the kidney had no response and psoriasis was still active. Furthermore, he received a standard myeloablative conditioning with high dose melphalan followed by ASCT. The erythema with slivery scales of psoriasis vulgaris gradually improved and almost disappeared after granulocyte implantation. He obtained persistent hematological complete remission, organ response and recovery of psoriasis. We report a rare case of AL amyloidosis coincidence with psoriasis treated by ASCT. The outcome of this patient indicated that ASCT has therapeutic values both in AL amyloidosis and AIDs.</abstract><cop>United States</cop><pub>the Author(s). Published by Wolters Kluwer Health, Inc</pub><pmid>30558027</pmid><doi>10.1097/MD.0000000000013589</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-7974
ispartof Medicine (Baltimore), 2018-12, Vol.97 (50), p.e13589-e13589
issn 0025-7974
1536-5964
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6320088
source Wolters Kluwer Open Health; MEDLINE; DOAJ Directory of Open Access Journals; IngentaConnect Free/Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection
subjects Antineoplastic Agents - therapeutic use
Bortezomib - therapeutic use
Clinical Case Report
Hematopoietic Stem Cell Transplantation - methods
Hematopoietic Stem Cell Transplantation - standards
Humans
Immunoglobulin Light-chain Amyloidosis - complications
Immunoglobulin Light-chain Amyloidosis - drug therapy
Immunosuppressive Agents - therapeutic use
Male
Melphalan - therapeutic use
Middle Aged
Psoriasis - complications
Psoriasis - drug therapy
Thalidomide - therapeutic use
Transplantation, Autologous - methods
title Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T10%3A50%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Complete%20remission%20of%20both%20immunoglobulin%20light%20chain%20amyloidosis%20and%20psoriasis%20after%20autologous%20hematopoietic%20stem%20cell%20transplantation:%20A%20case%20report&rft.jtitle=Medicine%20(Baltimore)&rft.au=Chen,%20Wencui&rft.date=2018-12-01&rft.volume=97&rft.issue=50&rft.spage=e13589&rft.epage=e13589&rft.pages=e13589-e13589&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000013589&rft_dat=%3Cpubmed_cross%3E30558027%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30558027&rfr_iscdi=true